LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

95.97 0.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

95.02

Massimo

97.78

Metriche Chiave

By Trading Economics

Entrata

2.9M

-47M

Vendite

16M

49M

Margine di Profitto

-96.144

Dipendenti

283

EBITDA

6.9M

-40M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+17.34% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

423M

6.4B

Apertura precedente

95.28

Chiusura precedente

95.97

Notizie sul Sentiment di mercato

By Acuity

43%

57%

151 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2025, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 set 2025, 21:59 UTC

Utili

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 set 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

17 set 2025, 23:39 UTC

Discorsi di Mercato

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 set 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 set 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 set 2025, 21:00 UTC

Utili

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

17 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 set 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 set 2025, 18:43 UTC

Discorsi di Mercato

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 set 2025, 18:38 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 set 2025, 18:20 UTC

Discorsi di Mercato

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 set 2025, 18:14 UTC

Discorsi di Mercato

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 set 2025, 17:59 UTC

Discorsi di Mercato

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 set 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 set 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 set 2025, 16:51 UTC

Utili

Correct: Exor 1H Net Loss -EUR624M

17 set 2025, 16:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 16:34 UTC

Discorsi di Mercato

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 set 2025, 16:25 UTC

Utili

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 set 2025, 16:23 UTC

Utili

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

17.34% in crescita

Previsioni per 12 mesi

Media 112.08 USD  17.34%

Alto 135 USD

Basso 95 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

13

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

60 / 65.58Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

151 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat